Genmab — Juni 2023

[Bulder]

Ja, her begynder det at ligne noget. Desværre dog kun fase 1.

[peter12]

Der kører også fase 3 studier https://www.jnj.com/new-long-term-data-from-the-chrysalis-study-show-median-progression-free-survival-not-reached-after-33-6-months-of-follow-up-with-first-line-use-of-rybrevant-amivantamab-vmjw-and-lazertinib-combination-therapy-in-patients-with-treatment-naive-egfr-mutated-advanced-non-small-cell-lung-cancer

[E_L]

the amivantamab posters are now all available https://www.congresshub.com/Oncology/AM2023

[E_L]

SC dosing of amivantamab significantly improved IRR safety profile (16% vs 67% for IV) https://www.congresshub.com/Oncology/AM2023/Amivantamab/Minchom#interactive_pdf That should make this drug much much more tolerable

[Bulder]

Peter 23:40: ja men jeg tvivler på at Mariposa når med på asco til næste år.

[E_L]

another Hemophilia trial for Daratumumab ITI Using SCT800 Combining Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor https://www.clinicaltrials.gov/ct2/show/NCT05888870

[E_L]

Janssen Presents Longer-Term Data for TECVAYLI (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma https://www.jnj.com/janssen-presents-longer-term-data-for-tecvayli-teclistamab-cqyv-showing-a-duration-of-response-of-22-months-in-patients-with-relapsed-or-refractory-multiple-myeloma

[E_L]

J&J’s multiple myeloma combo produces déjà vu with 96% Carvykti-like response https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response

[Bulder]

Jamen er det ikke hvad vi altid har sagt? Og når de så lægger dara oveni, så får vi ORR-rater på 105%. Jeg tør slet ikke tænke på, hvad der vi når op på, når superdara kommer.

[bibob]

Fra ASCO. https://www.fiercebiotech.com/biotech/jjs-new-multiple-myeloma-combo-produces-deja-vu-96-carvykti-response?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech+Tracker&oly_enc_id=6900G6464778A3A

[bibob]

Sorry. Havde ikke set E L link 21.07

[Solsen]

https://www.bt.dk/udland/nyt-studie-overrasker-pille-halverer-risikoen-for-at-doe-af-lungekraeft Osimertinib vækker opsigt. Amivantamab går efter det marked (Tagrisso) i kombi med Lazertinib.

[Pensionisten]

Fireside Goldman Sachs - desværre ikke Jan, der deltager (link)

[Pensionisten]

https://ir.genmab.com/genmab-news#content

[E_L]

Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price target of $51.00.

[Klarussen]

Lyder meget rimeligt

[bikube]

Den 22. maj hævede han fra 47 til 51. Det svarer til lidt over 3500 i DK.

[Solsen]

Lidt om Car-T https://endpts.com/new-car-t-data-look-spectacular-but-how-many-patients-will-take-it-and-when-asco23/

[E_L]

longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile https://twitter.com/lymphomahub/status/1666142892270682128

[Bulder]

Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt